The Spectrum Pharma Analyst
B Riley FBR analyst Mayank Mamtani maintained a Buy rating on Spectrum and lowered the price target from $18 to $11.
The Spectrum Pharma Thesis
The topline overall response rate of 14.8% Spectrum reported for Cohort 1 in the Phase 2 study that evaluated poziotinib in previously treated exon 20 deletion EGFR mutant non-small cell lung cancer patients came in below the 20-30% consensus and the 43% reported in the single-center MD Anderson study, Mamtani said in a Friday note. (See his track record here.)
This would mean the 115-patient study failed to meet the pre-specified threshold agreed upon with the FDA for accelerated approval, the analyst said.
Yet the data offered evidence of monotherapy activity, and the 68.7% disease control rate and 7.4 months of response are clinically meaningful in a hard-to-treat patient population, he said.
"While acknowledging cohort 1 results has readthrough to cohorts 2-7, we aren't convinced to take out pozi from our model as is reflected in today's sell-off, i.e., -60%, and believe incremental updates in 2020 to reaffirm confidence in pozi's place in NSCLC treatment paradigm."
B Riley FBR said it sees a valuation floor in the form of more advanced ROLONTIS for treatment of neutropenia that is likely to be commercially launched in the fourth quarter of 2020 — and the $250 million in cash the company has for supporting advancement of earlier stage oncology candidates.
Spectrum Pharma Price Action
The stock was trading 2.29% higher at $3.58 at the time of publication Friday.
10 Biotech M&A Targets Under The Scanner For 2020
Acasti Delays Data Readout For Drug To Treat Elevated Triglycerides
Latest Ratings for SPPI
View More Analyst Ratings for SPPI
View the Latest Analyst Ratings
See more from Benzinga
- The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping
- The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.